{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T04:00:29Z","timestamp":1783656029784,"version":"3.55.0"},"reference-count":89,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2021M701036"],"award-info":[{"award-number":["2021M701036"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["QN2022154"],"award-info":[{"award-number":["QN2022154"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["B2021003043"],"award-info":[{"award-number":["B2021003043"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science and Technology Project of Hebei Education Department","award":["2021M701036"],"award-info":[{"award-number":["2021M701036"]}]},{"name":"Science and Technology Project of Hebei Education Department","award":["QN2022154"],"award-info":[{"award-number":["QN2022154"]}]},{"name":"Science and Technology Project of Hebei Education Department","award":["B2021003043"],"award-info":[{"award-number":["B2021003043"]}]},{"name":"Hebei Province Postdoctoral Science Foundation","award":["2021M701036"],"award-info":[{"award-number":["2021M701036"]}]},{"name":"Hebei Province Postdoctoral Science Foundation","award":["QN2022154"],"award-info":[{"award-number":["QN2022154"]}]},{"name":"Hebei Province Postdoctoral Science Foundation","award":["B2021003043"],"award-info":[{"award-number":["B2021003043"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Streptococcus pyogenes (group A Streptococcus; GAS), a Gram-positive coccal bacterium, poses a significant global disease burden, especially in low- and middle-income countries. Its manifestations can range from pharyngitis and skin infection to severe and aggressive diseases, such as necrotizing fasciitis and streptococcal toxic shock syndrome. At present, although GAS is still sensitive to penicillin, there are cases of treatment failure for GAS pharyngitis, and antibiotic therapy does not universally prevent subsequent disease. In addition to strengthening global molecular epidemiological surveillance and monitoring of antibiotic resistance, developing a safe and effective licensed vaccine against GAS would be the most effective way to broadly address GAS-related diseases. Over the past decades, the development of GAS vaccines has been stalled, mainly because of the wide genetic heterogeneity of GAS and the diverse autoimmune responses to GAS. With outbreaks of scarlet fever in various countries in recent years, accelerating the development of a safe and effective vaccine remains a high priority. When developing a GAS vaccine, many factors need to be considered, including the selection of antigen epitopes, avoidance of self-response, and vaccine coverage. Given the challenges in GAS vaccine development, this review describes the important virulence factors that induce disease by GAS infection and how this has influenced the progression of vaccine development efforts, focusing on several candidate vaccines that are further along in development.<\/jats:p>","DOI":"10.3390\/vaccines11091510","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T21:08:36Z","timestamp":1695330516000},"page":"1510","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Streptococcus pyogenes: Pathogenesis and the Current Status of Vaccines"],"prefix":"10.3390","volume":"11","author":[{"given":"Jiachao","family":"Wang","sequence":"first","affiliation":[{"name":"Key Laboratory of Immune Mechanism and Intervention on Serious Disease in Hebei Province, Department of Immunology, Hebei Medical University, Shijiazhuang 050017, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiqing","family":"Ma","sequence":"additional","affiliation":[{"name":"Key Laboratory of Immune Mechanism and Intervention on Serious Disease in Hebei Province, Department of Immunology, Hebei Medical University, Shijiazhuang 050017, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Li","sequence":"additional","affiliation":[{"name":"Key Laboratory of Immune Mechanism and Intervention on Serious Disease in Hebei Province, Department of Immunology, Hebei Medical University, Shijiazhuang 050017, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Gao","sequence":"additional","affiliation":[{"name":"Key Laboratory of Immune Mechanism and Intervention on Serious Disease in Hebei Province, Department of Immunology, Hebei Medical University, Shijiazhuang 050017, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Immune Mechanism and Intervention on Serious Disease in Hebei Province, Department of Immunology, Hebei Medical University, Shijiazhuang 050017, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Dong","sequence":"additional","affiliation":[{"name":"Key Laboratory of Immune Mechanism and Intervention on Serious Disease in Hebei Province, Department of Immunology, Hebei Medical University, Shijiazhuang 050017, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wei","sequence":"additional","affiliation":[{"name":"Key Laboratory of Immune Mechanism and Intervention on Serious Disease in Hebei Province, Department of Immunology, Hebei Medical University, Shijiazhuang 050017, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S1473-3099(05)70267-X","article-title":"The global burden of group A streptococcal diseases","volume":"5","author":"Carapetis","year":"2005","journal-title":"Lancet Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1128\/CMR.00101-13","article-title":"Disease manifestations and pathogenic mechanisms of Group A Streptococcus","volume":"27","author":"Walker","year":"2014","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s41579-023-00865-7","article-title":"Pathogenesis, epidemiology and control of Group A Streptococcus infection","volume":"21","author":"Brouwer","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Auala, T., Zavale, B.G., Mbakwem, A.\u00c7., and Mocumbi, A.O. (2022). Acute Rheumatic Fever and Rheumatic Heart Disease: Highlighting the Role of Group A Streptococcus in the Global Burden of Cardiovascular Disease. Pathogens, 11.","DOI":"10.3390\/pathogens11050496"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0140-6736(05)66874-2","article-title":"Acute rheumatic fever","volume":"366","author":"Carapetis","year":"2005","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Wrighton, S., Ahnlide, V.K., Andr\u00e9, O., Bahnan, W., and Nordenfelt, P. (2023). Group A streptococci induce stronger M protein-fibronectin interaction when specific human antibodies are bound. Front. Microbiol., 14.","DOI":"10.3389\/fmicb.2023.1069789"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.chom.2013.11.003","article-title":"The globally disseminated M1T1 clone of group A Streptococcus evades autophagy for intracellular replication","volume":"14","author":"Barnett","year":"2013","journal-title":"Cell Host Microbe"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2200942","DOI":"10.2807\/1560-7917.ES.2023.28.1.2200942","article-title":"Increase in invasive group A streptococcal infection notifications, England, 2022","volume":"28","author":"Guy","year":"2023","journal-title":"Euro Surveill."},{"key":"ref_9","unstructured":"World Health Organization (2022, December 15). Disease Outbreak News; Increased Incidence of Scarlet Fever and Invasive Group A Streptococcus Infection\u2014Multi-Country. Available online: https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2022-DON429."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/cid\/ciw248","article-title":"Epidemiology of Invasive Group A Streptococcal Infections in the United States, 2005\u20132012","volume":"63","author":"Nelson","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3201\/eid2702.201945","article-title":"Increasing Incidence of Invasive Group A Streptococcus Disease in First Nations Population, Alberta, Canada, 2003\u20132017","volume":"27","author":"Tyrrell","year":"2021","journal-title":"Emerg. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/cid\/ciy1143","article-title":"The Path to Group A Streptococcus Vaccines: World Health Organization Research and Development Technology Roadmap and Preferred Product Characteristics","volume":"69","author":"Vekemans","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1128\/microbiolspec.GPP3-0054-2018","article-title":"Toxins and Superantigens of Group A Streptococci","volume":"7","author":"Shannon","year":"2019","journal-title":"Microbiol. Spectr."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.1074\/jbc.RA119.011258","article-title":"Structure-based group A streptococcal vaccine design: Helical wheel homology predicts antibody cross-reactivity among streptococcal M protein-derived peptides","volume":"295","author":"Aranha","year":"2020","journal-title":"J. Biol. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1462-5822.2004.00497.x","article-title":"Engagement of CD46 and alpha5beta1 integrin by group A streptococci is required for efficient invasion of epithelial cells","volume":"7","author":"Rezcallah","year":"2005","journal-title":"Cell Microbiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1084\/jem.164.5.1785","article-title":"Sequence of myosin-crossreactive epitopes of streptococcal M protein","volume":"164","author":"Dale","year":"1986","journal-title":"J. Exp. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.autrev.2015.04.005","article-title":"Post-infectious group A streptococcal autoimmune syndromes and the heart","volume":"14","author":"Martin","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s41564-017-0005-6","article-title":"Group A streptococcal M protein activates the NLRP3 inflammasome","volume":"2","author":"Valderrama","year":"2017","journal-title":"Nat. Microbiol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Bl\u00f6chl, C., Holzner, C., Luciano, M., Bauer, R., Horejs-Hoeck, J., Eckhard, U., Brandstetter, H., and Huber, C.G. (2021). Proteolytic Profiling of Streptococcal Pyrogenic Exotoxin B (SpeB) by Complementary HPLC-MS Approaches. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23010412"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"6253","DOI":"10.1074\/jbc.M704821200","article-title":"Group A streptococcal cysteine protease degrades C3 (C3b) and contributes to evasion of innate immunity","volume":"283","author":"Terao","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"7676","DOI":"10.1073\/pnas.90.16.7676","article-title":"Cleavage of interleukin 1 beta (IL-1 beta) precursor to produce active IL-1 beta by a conserved extracellular cysteine protease from Streptococcus pyogenes","volume":"90","author":"Kapur","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/s41586-021-04384-4","article-title":"Streptococcal pyrogenic exotoxin B cleaves GSDMA and triggers pyroptosis","volume":"602","author":"Deng","year":"2022","journal-title":"Nature"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.1016\/j.csbj.2022.08.018","article-title":"Exosite binding modulates the specificity of the immunomodulatory enzyme ScpA, a C5a inactivating bacterial protease","volume":"20","author":"Jain","year":"2022","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"7878","DOI":"10.1128\/IAI.73.12.7878-7886.2005","article-title":"Active and passive intranasal immunizations with streptococcal surface protein C5a peptidase prevent infection of murine nasal mucosa-associated lymphoid tissue, a functional homologue of human tonsils","volume":"73","author":"Park","year":"2005","journal-title":"Infect. Immun."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1086\/377700","article-title":"Immune response to group A streptococcal C5a peptidase in children: Implications for vaccine development","volume":"188","author":"Shet","year":"2003","journal-title":"J. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e01974-20","DOI":"10.1128\/mBio.01974-20","article-title":"Intracellular Group A Streptococcus Induces Golgi Fragmentation To Impair Host Defenses through Streptolysin O and NAD-Glycohydrolase","volume":"12","author":"Nozawa","year":"2021","journal-title":"mBio"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1086\/432729","article-title":"Vascular dysfunction and ischemic destruction of tissue in Streptococcus pyogenes infection: The role of streptolysin O-induced platelet\/neutrophil complexes","volume":"192","author":"Bryant","year":"2005","journal-title":"J. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1086\/603541","article-title":"Emerging role of the interleukin-8 cleaving enzyme SpyCEP in clinical Streptococcus pyogenes infection","volume":"200","author":"Turner","year":"2009","journal-title":"J. Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/j.1365-2958.2010.07065.x","article-title":"Chemokine-cleaving Streptococcus pyogenes protease SpyCEP is necessary and sufficient for bacterial dissemination within soft tissues and the respiratory tract","volume":"76","author":"Kurupati","year":"2010","journal-title":"Mol. Microbiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.csbj.2020.03.004","article-title":"Structure, dynamics and immunogenicity of a catalytically inactive CXC chemokine-degrading protease SpyCEP from Streptococcus pyogenes","volume":"18","author":"McKenna","year":"2020","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"108766","DOI":"10.1016\/j.celrep.2021.108766","article-title":"LL-37-mediated activation of host receptors is critical for defense against group A streptococcal infection","volume":"34","author":"Biswas","year":"2021","journal-title":"Cell Rep."},{"key":"ref_32","first-page":"709","article-title":"Failure of type-specific Streptococcus pyogenes vaccine to prevent respiratory infections","volume":"46","author":"Young","year":"1946","journal-title":"US Navy Med. Bull."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1084\/jem.110.2.271","article-title":"Persistence of type-specific antibodies in man following infection with group A streptococci","volume":"110","author":"Lancefikld","year":"1959","journal-title":"J. Exp. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1084\/jem.124.6.1135","article-title":"Antigenicity of the M proteins of group A hemolytic streptococci. 3. Antibody responses and cutaneous hypersensitivity in humans","volume":"124","author":"Fox","year":"1966","journal-title":"J. Exp. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1084\/jem.145.6.1469","article-title":"Purification and properties of M protein extracted from group A streptococci with pepsin: Covalent structure of the amino terminal region of type 24 M antigen","volume":"145","author":"Beachey","year":"1977","journal-title":"J. Exp. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1084\/jem.163.6.1451","article-title":"Opsonic antibodies evoked by hybrid peptide copies of types 5 and 24 streptococcal M proteins synthesized in tandem","volume":"163","author":"Beachey","year":"1986","journal-title":"J. Exp. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1084\/jem.166.3.647","article-title":"Protective immunogenicity and T lymphocyte specificity of a trivalent hybrid peptide containing NH2-terminal sequences of types 5, 6, and 24 M proteins synthesized in tandem","volume":"166","author":"Beachey","year":"1987","journal-title":"J. Exp. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0264-410X(98)00150-9","article-title":"Multivalent group A streptococcal vaccine designed to optimize the immunogenicity of six tandem M protein fragments","volume":"17","author":"Dale","year":"1999","journal-title":"Vaccine."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1128\/IAI.70.5.2734-2738.2002","article-title":"A lipid core peptide construct containing a conserved region determinant of the group A streptococcal M protein elicits heterologous opsonic antibodies","volume":"70","author":"Olive","year":"2002","journal-title":"Infect. Immun."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1086\/374800","article-title":"Protection against group A streptococcus by immunization with J8-diphtheria toxoid: Contribution of J8- and diphtheria toxoid-specific antibodies to protection","volume":"187","author":"Batzloff","year":"2003","journal-title":"J. Infect. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1128\/IAI.69.1.622-625.2001","article-title":"Characterization of the domain of fibronectin-binding protein I of Streptococcus pyogenes responsible for elicitation of a protective immune response","volume":"69","author":"Schulze","year":"2001","journal-title":"Infect. Immun."},{"key":"ref_42","first-page":"1115","article-title":"Rheumatic fever following streptococcal vaccination","volume":"207","author":"Massell","year":"1969","journal-title":"Report of three cases. JAMA"},{"key":"ref_43","unstructured":"Food and Drug Administration, HHS (2005). Revocation of status of specific products; Group A streptococcus. Direct final rule. Fed. Regist., 70, 72197\u201372199."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1473-3099(09)70178-1","article-title":"Global emm type distribution of group A streptococci: Systematic review and implications for vaccine development","volume":"9","author":"Steer","year":"2009","journal-title":"Lancet Infect. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1128\/IAI.70.4.2171-2177.2002","article-title":"Immunogenicity of a 26-valent group A streptococcal vaccine","volume":"70","author":"Hu","year":"2002","journal-title":"Infect. Immun."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1086\/444458","article-title":"Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers","volume":"41","author":"McNeil","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"8175","DOI":"10.1016\/j.vaccine.2011.09.005","article-title":"New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci","volume":"29","author":"Dale","year":"2011","journal-title":"Vaccine"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.vaccine.2013.01.019","article-title":"Potential coverage of a multivalent M protein-based group A streptococcal vaccine","volume":"31","author":"Dale","year":"2013","journal-title":"Vaccine"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e00429-20","DOI":"10.1128\/mSphere.00429-20","article-title":"Systematic Review and Meta-analysis of the Prevalence of Group A Streptococcal emm Clusters in Africa To Inform Vaccine Development","volume":"5","author":"Salie","year":"2020","journal-title":"mSphere"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"8250","DOI":"10.1016\/j.vaccine.2011.08.113","article-title":"HLA class II transgenic mice develop a safe and long lasting immune response against StreptInCor, an anti-group A streptococcus vaccine candidate","volume":"29","author":"Guerino","year":"2011","journal-title":"Vaccine"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Postol, E., Alencar, R., Higa, F.T., Freschi de Barros, S., Demarchi, L.M., Kalil, J., and Guilherme, L. (2013). StreptInCor: A candidate vaccine epitope against S. pyogenes infections induces protection in outbred mice. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0060969"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1016\/j.vaccine.2013.08.043","article-title":"Analysis of the coverage capacity of the StreptInCor candidate vaccine against Streptococcus pyogenes","volume":"32","author":"Alencar","year":"2014","journal-title":"Vaccine"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"9733","DOI":"10.1038\/s41598-019-46244-2","article-title":"Group A Streptococcus Adsorbed Vaccine: Repeated Intramuscular Dose Toxicity Test in Minipigs","volume":"9","author":"Postol","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"5915","DOI":"10.4049\/jimmunol.1500157","article-title":"A synthetic M protein peptide synergizes with a CXC chemokine protease to induce vaccine-mediated protection against virulent streptococcal pyoderma and bacteremia","volume":"194","author":"Pandey","year":"2015","journal-title":"J. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.4049\/jimmunol.1501994","article-title":"Combinatorial Synthetic Peptide Vaccine Strategy Protects against Hypervirulent CovR\/S Mutant Streptococci","volume":"196","author":"Pandey","year":"2016","journal-title":"J. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"13786","DOI":"10.1038\/s41598-017-14157-7","article-title":"Physicochemical characterisation, immunogenicity and protective efficacy of a lead streptococcal vaccine: Progress towards Phase I trial","volume":"7","author":"Pandey","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Sekuloski, S., Batzloff, M.R., Griffin, P., Parsonage, W., Elliott, S., Hartas, J., O\u2019Rourke, P., Marquart, L., Pandey, M., and Rubin, F.A. (2018). Evaluation of safety and immunogenicity of a group A streptococcus vaccine candidate (MJ8VAX) in a randomized clinical trial. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0198658"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"39274","DOI":"10.1038\/srep39274","article-title":"Novel platform technology for modular mucosal vaccine that protects against streptococcus","volume":"6","author":"Zaman","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Faruck, M.O., Zhao, L., Hussein, W.M., Khalil, Z.G., Capon, R.J., Skwarczynski, M., and Toth, I. (2020). Polyacrylate-Peptide Antigen Conjugate as a Single-Dose Oral Vaccine against Group A Streptococcus. Vaccines, 8.","DOI":"10.3390\/vaccines8010023"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41541-023-00604-2","article-title":"Streptococcus pyogenes vaccine candidates do not induce autoimmune responses in a rheumatic heart disease model","volume":"8","author":"Reynolds","year":"2023","journal-title":"NPJ Vaccines"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e03537-20","DOI":"10.1128\/mBio.03537-20","article-title":"Prime-Pull Immunization with a Bivalent M-Protein and Spy-CEP Peptide Vaccine Adjuvanted with CAF\u00ae01 Liposomes Induces Both Mucosal and Peripheral Protection from covR\/S Mutant Streptococcus pyogenes","volume":"12","author":"Ozberk","year":"2021","journal-title":"mBio"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41541-023-00609-x","article-title":"The Streptococcus pyogenes vaccine landscape","volume":"8","author":"Walkinshaw","year":"2023","journal-title":"NPJ Vaccines"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41541-023-00695-x","article-title":"Polymeric epitope-based vaccine induces protective immunity against group A Streptococcus","volume":"8","author":"Chen","year":"2023","journal-title":"NPJ Vaccines"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41541-023-00639-5","article-title":"Progress towards a glycoconjugate vaccine against Group A Streptococcus","volume":"8","author":"Burns","year":"2023","journal-title":"NPJ Vaccines"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"120736","DOI":"10.1016\/j.carbpol.2023.120736","article-title":"Elucidating the role of N-acetylglucosamine in Group A Carbohydrate for the development of an effective glycoconjugate vaccine against Group A Streptococcus","volume":"311","author":"Pitirollo","year":"2023","journal-title":"Carbohydr. Polym."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e00618-16","DOI":"10.1128\/mBio.00618-16","article-title":"Differing Efficacies of Lead Group a Streptococcal Vaccine Candidates and Full-Length M Protein in Cutaneous and Invasive Disease Models","volume":"7","author":"Pandey","year":"2016","journal-title":"mBio"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1021\/acs.jmedchem.0c01660","article-title":"Poly(hydrophobic amino acid)-Based Self-Adjuvanting Nanoparticles for Group A Streptococcus Vaccine Delivery","volume":"64","author":"Azuar","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Di Benedetto, R., Mancini, F., Carducci, M., Gasperini, G., Moriel, D.G., Saul, A., Necchi, F., Rappuoli, R., and Micoli, F. (2020). Rational Design of a Glycoconjugate Vaccine against Group A Streptococcus. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21228558"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"M111.015693","DOI":"10.1074\/mcp.M111.015693","article-title":"Multi high-throughput approach for highly selective identification of vaccine candidates: The Group A Streptococcus case","volume":"11","author":"Bensi","year":"2012","journal-title":"Mol. Cell Proteomics"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e00693-19","DOI":"10.1128\/mBio.00693-19","article-title":"An Experimental Group A Streptococcus Vaccine That Reduces Pharyngitis and Tonsillitis in a Nonhuman Primate Model","volume":"10","author":"Carnathan","year":"2019","journal-title":"mBio"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e00122-20","DOI":"10.1128\/mBio.00122-20","article-title":"Vaccine-Induced Th1-Type Response Protects against Invasive Group A Streptococcus Infection in the Absence of Opsonizing Antibodies","volume":"11","author":"Rhyme","year":"2020","journal-title":"mBio"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1038\/s41598-021-83673-4","article-title":"A multivalent T-antigen-based vaccine for Group A Streptococcus","volume":"11","author":"Loh","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.chom.2014.05.009","article-title":"The classical lancefield antigen of group a Streptococcus is a virulence determinant with implications for vaccine design","volume":"15","author":"Cole","year":"2014","journal-title":"Cell Host Microbe"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e02600","DOI":"10.1128\/mBio.02600-19","article-title":"A Multicomponent Vaccine Provides Immunity against Local and Systemic Infections by Group A Streptococcus across Serotypes","volume":"10","author":"Bi","year":"2019","journal-title":"mBio."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1172\/JCI80792","article-title":"Group A Streptococcus intranasal infection promotes CNS infiltration by streptococcal-specific Th17 cells","volume":"126","author":"Dileepan","year":"2016","journal-title":"J. Clin. Invest."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jinf.2016.02.002","article-title":"Development of a multicomponent vaccine for Streptococcus pyogenes based on the antigenic targets of IVIG","volume":"72","author":"Reglinski","year":"2016","journal-title":"J. Infect."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1038\/s41467-020-17299-x","article-title":"Cross-serotype protection against group A Streptococcal infections induced by immunization with SPy_2191","volume":"11","author":"Sanduja","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_78","first-page":"ciad311","article-title":"Safety of Streptococcus pyogenes vaccines: Anticipating and Overcoming Challenges for Clinical Trials and Post Marketing Monitoring","volume":"26","author":"Asturias","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"104609","DOI":"10.1016\/j.meegid.2020.104609","article-title":"Global genomic epidemiology of Streptococcus pyogenes","volume":"86","author":"Jespersen","year":"2020","journal-title":"Infect. Genet. Evol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/QCO.0000000000000644","article-title":"Update on group A streptococcal vaccine development","volume":"33","author":"Dale","year":"2020","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Azuar, A., Jin, W., Mukaida, S., Hussein, W.M., Toth, I., and Skwarczynski, M. (2019). Recent Advances in the Development of Peptide Vaccines and Their Delivery Systems Against Group A Streptococcus. Vaccines, 7.","DOI":"10.3390\/vaccines7030058"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Yang, J., Boer, J.C., Khongkow, M., Phunpee, S., Khalil, Z.G., Bashiri, S., Deceneux, C., Goodchild, G., Hussein, W.M., and Capon, R.J. (2023). The Development of Surface-Modified Liposomes as an Intranasal Delivery System for Group A Streptococcus Vaccines. Vaccines, 11.","DOI":"10.3390\/vaccines11020305"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Forster, A.H., Witham, K., Depelsenaire, A.C.I., Veitch, M., Wells, J.W., Wheatley, A., Pryor, M., Lickliter, J.D., Francis, B., and Rockman, S. (2020). Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial. PLoS Med., 17.","DOI":"10.1371\/journal.pmed.1003024"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41541-020-00222-2","article-title":"M-protein based vaccine induces immunogenicity and protection from Streptococcus pyogenes when delivered on a high-density microarray patch (HD-MAP)","volume":"5","author":"Mills","year":"2020","journal-title":"NPJ Vaccines"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.cell.2022.03.044","article-title":"Circular RNA vaccines against SARS-CoV-2 and emerging variants","volume":"185","author":"Qu","year":"2022","journal-title":"Cell"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/s41591-022-02162-x","article-title":"Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster","volume":"29","author":"Kurhade","year":"2023","journal-title":"Nat. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"115042","DOI":"10.1016\/j.addr.2023.115042","article-title":"Engineering nanoparticle toolkits for mRNA delivery","volume":"200","author":"Sun","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jconrel.2021.03.027","article-title":"Delivery of nanoparticle antigens to antigen-presenting cells: From extracellular specific targeting to intracellular responsive presentation","volume":"333","author":"Wang","year":"2021","journal-title":"J. Control. Release"},{"key":"ref_89","unstructured":"(2023, January 14). Strep A Vaccine Global Consortium (SAVAC) (International Vaccine Institute SAVAC Team). Available online: https:\/\/savac.ivi.int."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/9\/1510\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:55:15Z","timestamp":1760129715000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/9\/1510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,21]]},"references-count":89,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["vaccines11091510"],"URL":"https:\/\/doi.org\/10.3390\/vaccines11091510","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,21]]}}}